BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30183583)

  • 21. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
    Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):111-7. PubMed ID: 16431313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
    Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
    Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
    Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
    Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
    Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
    J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Significance of Preoperative Hepatocellular Carcinoma With High
    Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H
    Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.
    Lok AS; Sterling RK; Everhart JE; Wright EC; Hoefs JC; Di Bisceglie AM; Morgan TR; Kim HY; Lee WM; Bonkovsky HL; Dienstag JL;
    Gastroenterology; 2010 Feb; 138(2):493-502. PubMed ID: 19852963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
    Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.
    Wang CS; Lin CL; Lee HC; Chen KY; Chiang MF; Chen HS; Lin TJ; Liao LY
    World J Gastroenterol; 2005 Oct; 11(39):6115-9. PubMed ID: 16273636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
    J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma.
    Hatanaka T; Kakizaki S; Shimada Y; Takizawa D; Katakai K; Yamazaki Y; Sato K; Kusano M; Yamada M
    Intern Med; 2016; 55(16):2163-71. PubMed ID: 27522991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
    Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A high value of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with long-term liver dysfunction after treatment.
    Saito M; Seo Y; Yano Y; Miki A; Yoshida M; Azuma T
    J Gastroenterol; 2012 Oct; 47(10):1134-42. PubMed ID: 22441533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Predictive Power of Serum α-Fetoprotein and Des-γ-Carboxy Prothrombin for Survival Varies by Tumor Size in Hepatocellular Carcinoma.
    Tsugawa D; Fukumoto T; Kido M; Takebe A; Tanaka M; Kuramitsu K; Matsumoto I; Ajiki T; Koyama T; Ku Y
    Kobe J Med Sci; 2015 Mar; 61(5):E124-31. PubMed ID: 27363395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.